Hormosan Pharma GmbH

Hormosan Pharma GmbH is a German pharmaceutical company that has been providing prescription pharmaceuticals to the German market for over 50 years. The company focuses on three core therapeutic areas: rare diseases in neurology, pain therapy for chronic pain and headaches, and sexual health, with a focus on oral contraceptives, erectile dysfunction, and HIV. The company offers a large portfolio of innovative medicines and generics, addressing unmet patient needs. Hormosan's specific formulations and dosage forms enhance patient benefits and compliance, while its generics provide high-quality therapeutic options at attractive pricing.

In 2008, Hormosan was acquired by the international pharmaceutical LUPIN Group, which has enabled the company to be embedded in a global network, enhancing its competitiveness and allowing it to provide long-term attractive therapeutic options to patients in the German market. The company's focus on addressing unmet patient needs, along with its diverse portfolio of pharmaceuticals, positions it well in the competitive German pharmaceutical industry.

Given its strong presence in the German pharmaceutical market and its focus on critical therapeutic areas, Hormosan Pharma GmbH presents an attractive investment opportunity for venture capitalists looking to invest in the health care and pharmaceutical industries in Germany.